{
    "clinical_study": {
        "@rank": "127768", 
        "acronym": "PRECO-CI", 
        "arm_group": {
            "arm_group_label": "HIV+ patients with an estimated date of seroconversion", 
            "description": "It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study."
        }, 
        "biospec_descr": {
            "textblock": "Plasma and whole blood for PBMC preparation"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Set-up of a biobank for patients with an estimated date of infection seroconverters: store\n      plasma and cells samples at initial contact and during follow-up for future analysis and\n      analysis in international collaborative cohort seroconverters."
        }, 
        "brief_title": "Early Identification and Treatment of Early HIV Infection in C\u00f4te d'Ivoire", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients included in the last Primo-CI ANRS 1220 protocol\n\n          -  All HIV infected individuals diagnosed during a blood donation with an estimated date\n             of HIV seroconversion that will respect the following criteria:  (i) age \u226518 (ii)\n             HIV-1 or HIV-1+2 infected, (iii) HIV-seronegative at the preceding donation; (iv) who\n             returned to the clinic to be informed of their HIV test result (v) with an HIV\n             serology confirmed with two specific tests in two different laboratories (vi) who\n             have never received ART for curative purpose\n\n          -  informed on study objectives and have a signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Patient living outside of Abidjan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All HIV infected individuals that will have had a contact with the Blood Bank Medical\n        Center since 1992."
            }
        }, 
        "enrollment": {
            "#text": "564", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917175", 
            "org_study_id": "ANRS 1220/12277 PRECO-CI"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "Cohort", 
            "Early HIV infection", 
            "C\u00f4te d'Ivoire", 
            "Disease progression"
        ], 
        "lastchanged_date": "August 5, 2013", 
        "link": [
            {
                "description": "Sponsor site", 
                "url": "http://anrs.fr/"
            }, 
            {
                "description": "Methodology centre site", 
                "url": "http://mereva.net"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "plasmaci@yahoo.fr", 
                    "last_name": "Seidou Konat\u00e9, MD", 
                    "phone": "+22521355723"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Centre National de Transfusion Sanguine (National Blood Transfusion Centre)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "minga.albert@yahoo.fr", 
                    "last_name": "Albert Kla Minga, MD, PhD", 
                    "phone": "+225 21 35 52 78"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Centre M\u00e9dical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "C\u00f4te D'Ivoire"
        }, 
        "number_of_groups": "1", 
        "official_title": "Research Platform \" Early Identification and Treatment of Early HIV Infection in C\u00f4te d'Ivoire \"", 
        "overall_contact": {
            "email": "minga.albert@yahoo.fr", 
            "last_name": "Albert Minga, MD, PhD", 
            "phone": "+225 21 35 52 78"
        }, 
        "overall_contact_backup": {
            "email": "ahuatchi@gmail.com", 
            "last_name": "Patrick Coffie, MD, PhD", 
            "phone": "+225 21 75 59 60"
        }, 
        "overall_official": [
            {
                "affiliation": "CMSDS, Abidjan, C\u00f4te d'Ivoire", 
                "last_name": "Albert Kla Minga, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Programme PACCI, Abidjan, C\u00f4te d'Ivoire", 
                "last_name": "Patrick Coffie, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de Sant\u00e9 Publique, d'Epid\u00e9miologie et de D\u00e9veloppement (ISPED), Bordeaux, France", 
                "last_name": "Charlotte Lewden, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS", 
            "measure": "Natural history of HIV infection in Sub-Saharan Africa", 
            "safety_issue": "No", 
            "time_frame": "12 months after ART initiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation", 
                "measure": "Estimate the probability of disease progression after HIV seroconversion", 
                "safety_issue": "No", 
                "time_frame": "12 months after ART initiation"
            }, 
            {
                "description": "CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA", 
                "measure": "Evolution of markers of HIV infection and immunity", 
                "safety_issue": "No", 
                "time_frame": "12 months after ART initiation"
            }, 
            {
                "description": "biomolecular analysis of HIV-1", 
                "measure": "Viral genetic diversity description", 
                "safety_issue": "No", 
                "time_frame": "Inclusion (J0)"
            }, 
            {
                "description": "Frequency of primary resistance to antiretroviral treatment (genotyping)", 
                "measure": "Primary resistance to antiretroviral treatment", 
                "safety_issue": "No", 
                "time_frame": "Inclusion (J0)"
            }, 
            {
                "description": "Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements", 
                "measure": "Metabolic and lipodystrophic disorders", 
                "safety_issue": "No", 
                "time_frame": "12 months after ART initiation"
            }, 
            {
                "description": "Occurence of pregnancies", 
                "measure": "Incidence of pregnancies", 
                "safety_issue": "No", 
                "time_frame": "12 months after ART initiation"
            }, 
            {
                "description": "Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry", 
                "measure": "T lymphocytes activation and evolution in seroconverters", 
                "safety_issue": "No", 
                "time_frame": "Inclusion"
            }, 
            {
                "description": "Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry", 
                "measure": "T lymphocytes activation and evolution in seroconverters", 
                "safety_issue": "No", 
                "time_frame": "12 months after ART initiation"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1997", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}